New injection could help sleep apnea without CPAP
NCT ID NCT07387094
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tests an injectable drug called XW003 (Ecnoglutide) in 140 obese adults with obstructive sleep apnea who do not use CPAP machines. The goal is to see if the drug reduces breathing pauses during sleep and helps with weight loss. Participants receive either the drug or a placebo for several months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- XW003 (Ecnoglutide) injection
- What this could lead to
- If successful, this could offer a drug-based option to reduce sleep apnea severity and body weight without needing a CPAP machine.
- What could go wrong
- This is still an experimental drug in a mid-sized trial. It may not work for everyone, and side effects like nausea or digestive issues are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University People's Hospital
RECRUITINGBeijing, Beijing Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?
- Can stomach surgery alter how painkillers work?